tradingkey.logo

ClearPoint Neuro prelim Q4 revenue rises

ReutersJan 12, 2026 1:40 PM


Overview

  • Device and therapy firm's preliminary Q4 revenue rose 20% yr/yr to $10.4 mln

  • Company expects 2026 revenue between $54 mln and $60 mln

  • Preliminary results show growth in neurosurgery disposables and biologics delivery


Outlook

  • ClearPoint Neuro expects 2026 revenue between $54 mln and $60 mln

  • Company anticipates double-digit growth in all four existing markets in 2026

  • ClearPoint Neuro plans commercial launch of neuro cell and gene therapies in future


Result Drivers

  • NEUROSURGERY AND BIOLOGICS GROWTH - Functional neurosurgery disposables and biologics and drug delivery saw growth rates of 23% and 26% respectively, according to CEO Joe Burnett

  • IRRAFLOW CONTRIBUTION - Revenue growth partially included sales from the newly acquired IRRAflow product line


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Slight Beat*

$10.40 mln

$10.30 mln (2 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Clearpoint Neuro Inc is $29.00, about 94.4% above its January 9 closing price of $14.92

Press Release: ID:nACSSSgFDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI